Abstract
In the midst of the global pandemic of COVID-19 and its significant morbidity and mortality reported across the world due to severe acute respiratory distress syndrome (SARS), it has always been posing a new set of complications each passing day. As we are still in the process of understanding about the complications related to COVID-19, we are encountered with complications related to immunization for COVID-19. We are reporting a case of facial onset Guillain-Barré syndrome (GBS) in the patient who received first dose of COVISHIELD vaccine a couple of weeks prior to the onset of his illness.
Highlights
After its initial recognition in Wuhan, China, the COVID-19 took little time in becoming a global pandemic taking lives of thousands of people across the world (1)
We report the first case of facial onset Guillain-Barré syndrome (GBS) after the first dose of COVISHIELD vaccine in India
With the mass vaccination campaign on the way world-wide, it is imperative for the clinicians to be aware of the possible complications of the vaccines; their identification at the earliest and management is far more crucial
Summary
After its initial recognition in Wuhan, China, the COVID-19 took little time in becoming a global pandemic taking lives of thousands of people across the world (1). Considering the predominant deficit bilateral facial weakness, he was further evaluated for bilateral facial palsy He had a history of poorly controlled diabetes with the blood sugar level at the the time of presentation being 323 mg/dl. A repeat nerve conduction study was performed at this time and it revealed further prolongation of distal latencies and reduction in CMAP amplitudes His motor functions remained as such for the [2,3] days he started to show improvement in his facial muscles. In the few days his serum sodium level stabilized and his motor functions improved further He was concurrently evaluated for the possible cause of right basifrontal granuloma; no specific etiology could be identified so far.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
